Impaired brain glucose metabolism leads to Alzheimer neurofibrillary degeneration through a decrease in tau O-GlcNAcylation
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Neurofibrillary degeneration characterized by abnormal hyperphosphorylation and aggregation of tau in affected neurons is directly associated with dementia symptoms and plays a pivotal role in the pathogenesis of Alzheimer disease (AD) and related tauopathies. It is well established that brain glucose uptake/metabolism is impaired in AD, but how this impairment contributes to the disease is unknown. We recently found that tau in human brain is also modified by O-GlcNAcylation in addition to phosphorylation and that the former negatively regulates the latter. On the basis of these findings, we propose a novel hypothesis that the impaired glucose uptake/metabolism contributes to AD by facilitating abnormal hyperphosphorylation of tau. Further studies of this mechanism are likely to offer a novel therapeutic target for preventing and treating AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A68: a Major Subunit of Paired Helical Filaments and Derivatized Forms of Normal Tau
Lee, V. M.-Y., Balin, B. J., Otvos, L., & Trojanowski, J. Q. (1991) · Science · doi:10.1126/science.1899488 · Cited by 1,418 · cited 1×
“Because the major protein component of PHFs and SFs is abnormallymodified tau [2–6], these neurodegenerativediseases are collectively called tauopathies [1].”
Cited by
Defeating Alzheimer's disease and other dementias: a priority for European science and society
Winblad, B., Amouyel, P., Andrieu, S., Ballard, C., Brayne, C., Brodaty, H., Cedazo-Minguez, A., Dubois, B., Edvardsson, D., Feldman, H., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00062-4 · Cited by 1,676
Self-citationTau and neurodegenerative disease: the story so far
Iqbal, K., Liu, F., & Gong, C.-X. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.225 · Cited by 806
Self-citationGong, C.-X., & Iqbal, K. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708785909111 · Cited by 644
Self-citationPost-translational modifications of tau protein: Implications for Alzheimer's disease
Martin, L., Latypova, X., & Terro, F. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2010.12.023 · Cited by 641
Mechanisms of tau-induced neurodegeneration
Iqbal, K., Liu, F., Gong, C.-X., Alonso, A. D. C., & Grundke-Iqbal, I. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0486-3 · Cited by 628
Self-citationWang, J.-Z., Xia, Y.-Y., Grundke-Iqbal, I., & Iqbal, K. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-129031 · Cited by 532
Self-citationDeficient brain insulin signalling pathway in Alzheimer's disease and diabetes
Liu, Y., Liu, F., Grundke‐Iqbal, I., Iqbal, K., & Gong, C. (2011) · The Journal of Pathology · doi:10.1002/path.2912 · Cited by 502
Self-citationThe role of tau in neurodegeneration
Gendron, T. F., & Petrucelli, L. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-13 · Cited by 478
“Based on these findings, it was proposed that impaired glucose metabolism in AD may contribute to disease pathogenesis by reducing tau O-GlcNAcylation and, consequently, increasing tau phosphorylation [143].”
The Role of Tau in Alzheimer's Disease and Related Disorders
Medeiros, R., Baglietto‐Vargas, D., & LaFerla, F. M. (2011) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00177.x · Cited by 432
Butkinaree, C., Park, K., & Hart, G. W. (2010) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2009.07.018 · Cited by 415
Microtubule-associated protein tau in development, degeneration and protection of neurons
Wang, J.-Z., & Liu, F. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.03.002 · Cited by 398
Self-citationLiu, Y., Liu, F., Iqbal, K., Grundke-Iqbal, I., & Gong, C.-X. (2008) · FEBS Letters · doi:10.1016/j.febslet.2007.12.035 · Cited by 394
Self-citationPresenilins Are Enriched in Endoplasmic Reticulum Membranes Associated with Mitochondria
Area-Gomez, E., de Groof, A. J. C., Boldogh, I., Bird, T. D., Gibson, G. E., Koehler, C. M., Yu, W. H., Duff, K. E., Yaffe, M. P., Pon, L. A., et al. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.090219 · Cited by 369
Involvement of Lipids in Alzheimer’s Disease Pathology and Potential Therapies
Chew, H., Solomon, V. A., & Fonteh, A. N. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00598 · Cited by 353
The role of protein glycosylation in Alzheimer disease
Schedin‐Weiss, S., Winblad, B., & Tjernberg, L. O. (2014) · The FEBS Journal · doi:10.1111/febs.12590 · Cited by 317
Alfaro, J. F., Gong, C.-X., Monroe, M. E., Aldrich, J. T., Clauss, T. R. W., Purvine, S. O., Wang, Z., Camp, D. G., Shabanowitz, J., Stanley, P., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200425109 · Cited by 300
Self-citationMyeloid-Cell-Derived VEGF Maintains Brain Glucose Uptake and Limits Cognitive Impairment in Obesity
Jais, A., Solas, M., Backes, H., Chaurasia, B., Kleinridders, A., Theurich, S., Mauer, J., Steculorum, S. M., Hampel, B., Goldau, J., et al. (2016) · Cell · doi:10.1016/j.cell.2016.03.033 · Cited by 252
“…in obesity, and brain glucose uptake is a critical determinant of the progression of neurodegenerative disorders such as Alzheimer’s disease (AD) (Gong et al., 2006; Winkler et al., 2015), we decided to address whether myeloid-cell-derived VEGF is also required to limit neurodegeneration in…”
BackgroundJazvinšćak Jembrek, M., Hof, P. R., & Šimić, G. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/346783 · Cited by 244
“Namely, abnormal metabolic changes, including pronounced decrease in glucose uptake and metabolism, are also characteristic for AD brain (for review see [96–99]).”
BackgroundSuccessful therapies for Alzheimer’s disease: why so many in animal models and none in humans?
Franco, R., & Cedazo-Minguez, A. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00146 · Cited by 183
Timper, K., del Río-Martín, A., Cremer, A. L., Bremser, S., Alber, J., Giavalisco, P., Varela, L., Heilinger, C., Nolte, H., Trifunovic, A., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.05.001 · Cited by 170
Cavaleri, F., & Bashar, E. (2018) · Journal of Nutrition and Metabolism · doi:10.1155/2018/7195760 · Cited by 126
Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
Golde, T. E. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01201-2 · Cited by 119
“1 3 aggregates and is thought to compete for phosphorylation at those residues [153].”
BackgroundGlucose metabolism and AD: evidence for a potential diabetes type 3
González, A., Calfío, C., Churruca, M., & Maccioni, R. B. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-00996-8 · Cited by 112
“Abbreviations AD: Alzheimer’s disease; NFT: Neurofibrillary tangles; APP: Amyloid precursor protein; UPR: Unfolded protein response; APO-E: Apolipoprotein E; GLUT: Glucose transporters; ATP: Adenosine-tri-phosphate; DTII: Diabetes type 2; JNKs: c-Jun N-terminal kinases; ER: Endoplasmic reticulum; UP: Unfolded proteins…”
BackgroundInfluentialMediators of tau phosphorylation in the pathogenesis of Alzheimer’s disease
Hanger, D. P., Seereeram, A., & Noble, W. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.104 · Cited by 98
Do, T. M., Alata, W., Dodacki, A., Traversy, M.-T., Chacun, H., Pradier, L., Scherrmann, J.-M., Farinotti, R., Calon, F., & Bourasset, F. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.02.010 · Cited by 77
Dysregulation of tau phosphorylation in mouse brain during excitotoxic damage.
Liang, Z., Liu, F., Iqbal, K., Grundke-Iqbal, I., & Gong, C.-X. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-1069 · Cited by 73
“The phosphorylation level of tau is regulated by tau protein kinases and phosphatases as well as other modifications, such as O-GlcNAcylation [6,7], of tau itself.”
Self-citationTau-targeting therapy in Alzheimer’s disease: Critical advances and future opportunities
Guo, Y., Li, S., Zeng, L.-H., & Tan, J. (2022) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2022.16 · Cited by 61
Role of Microglia in Regulating Cholesterol and Tau Pathology in Alzheimer’s Disease
Nanjundaiah, S., Chidambaram, H., Chandrashekar, M., & Chinnathambi, S. (2021) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-020-00883-6 · Cited by 36
Metadata
- Authors
- Gong, C.-X., Liu, F., Grundke-Iqbal, I., & Iqbal, K.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2006-04-06
- Volume
- 9
- Issue
- 1
- Pages
- 1-12
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W307967064
- Cited by
- 136
- References
- 1
- FWCI
- 4.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.